MAP3K5 and hepatocellular carcinoma: Epigenetic silencing of GCH1 promotes HCC cell growth by inhibiting the de novo synthesis of BH4 and activating the superoxide anion mediated ASK1/p38 signaling pathway, suggesting that targeting the GCH1/BH4 pathway may be a promising therapeutic strategy against HCC (45).